Clinical Trials

Inclusion Criteria.

• Patients must be adults, over the age of 18.
• English speaking.
• Scheduled to receive at least 3 months of oxaliplatin based chemotherapy, with no other highly neurotoxic agents (cisplatin, a taxane, a vinca-alkaloid, thalidomide, or bortezomib).  
• Patients who are planning to receive oxaliplatin based chemotherapy as part of a clinical trial will not be specifically excluded from participating on this trial.
• Participants who have medications prescribed for pain or anxiety will be included; however, they will be asked not to take any as needed (prn) pain or anxiety medications for 4 hours prior to QST, unless their pain or anxiety is severe (7 or higher on a scale of 0-10) in order to minimize influence of these medications on results.

Exclusion Criteria. 

• Patients with pre-existing neuropathy (greater than 2 on a 0-10 scale), major psychiatric condition (bipolar or schizophrenia) or whose prior medical history could interfere with their ability to fulfill study requirements or provide accurate self-report data will be excluded from participation. 
• Participants will be screened for these conditions by a review of their medical record and by collection of self-reported information.

Eligibility last updated 3/10/22. Questions regarding updates should be directed to the study team contact.